AstraZeneca PLC (AZN) Earnings History
Annual and quarterly earnings data from 1990 to 2025
Loading earnings history...
AZN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AZN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.9% | 23.4% | 17.5% |
| 2024 | 81.1% | 18.5% | 13.0% |
| 2023 | 82.0% | 17.9% | 13.0% |
| 2022 | 72.1% | 8.5% | 7.4% |
| 2021 | 66.8% | 2.8% | 0.3% |
Download Data
Export AZN earnings history in CSV or JSON format
Free sign-in required to download data
AstraZeneca PLC (AZN) Earnings Overview
As of May 6, 2026, AstraZeneca PLC (AZN) reported trailing twelve-month net income of $10.39B, reflecting +190.7% year-over-year growth. The company earned $6.66 per diluted share over the past four quarters, with a net profit margin of 17.5%.
Looking at the long-term picture, AZN's 5-year EPS compound annual growth rate (CAGR) stands at +21.8%, indicating exceptional earnings growth. The company achieved its highest annual net income of $10.26B in fiscal 2025, representing a new all-time high.
AstraZeneca PLC maintains industry-leading profitability with a gross margin of 81.9%, operating margin of 23.4%, and net margin of 17.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PFE ($7.49B net income, 12.4% margin), MRK ($18.25B net income, 28.1% margin), LLY ($25.27B net income, 31.7% margin), AZN has outperformed on profitability metrics. Compare AZN vs PFE →
AZN Earnings vs Peers
Earnings metrics vs comparable public companies
AZN Historical Earnings Data (1990–2025)
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.26B | +45.8% | $13.74B | $6.54 | 17.5% | 23.4% |
| 2024 | $7.04B | +18.1% | $10.00B | $2.25 | 13.0% | 18.5% |
| 2023 | $5.96B | +81.1% | $8.19B | $3.81 | 13.0% | 17.9% |
| 2022 | $3.29B | +2835.7% | $3.76B | $2.11 | 7.4% | 8.5% |
| 2021 | $112M | -96.5% | $1.06B | $0.08 | 0.3% | 2.8% |
| 2020 | $3.20B | +139.4% | $5.16B | $2.44 | 12.0% | 19.4% |
| 2019 | $1.33B | -38.1% | $2.92B | $1.03 | 5.5% | 12.0% |
| 2018 | $2.15B | -28.2% | $3.39B | $1.70 | 9.8% | 15.3% |
| 2017 | $3.00B | -14.2% | $3.68B | $2.37 | 13.4% | 16.4% |
| 2016 | $3.50B | +23.9% | $4.90B | $2.76 | 15.2% | 21.3% |
Full AZN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AZN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AZN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
Is AZN growing earnings?
AZN EPS is $6.66, with earnings growth accelerating to +190.7%. This exceeds the 5-year CAGR of +21.8%. TTM net income reached $10.4B.
What are AZN's profit margins?
AstraZeneca PLC net margin is +17.5%, with operating margin at +23.4%. Above-average margins indicate pricing power.
How consistent are AZN's earnings?
AZN earnings data spans 1990-2025. The accelerating earnings trend is +190.7% YoY. Historical data enables comparison across business cycles.